Pricing Log in Create free account
Saturday 17 October 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%
Market cap
$64.0B
P/E
17.9×
Fwd P/E
17.8×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Boston Scientific Corporation 8-K filed May 5, 2026

Period ended Apr 30, 2026 · Filed · accepted 4:47 PM ET · Document on sec.gov · Filing index

5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits